MCMCB Pro
D03.9

D03.9Melanoma in situ, unspecified

Billable / specific codeICD-10-CM

D03.9 is a billable, specific ICD-10-CM code for melanoma in situ, unspecified. It is valid for submission on a claim.

Risk adjustment

D03.9 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:

  • HCC 23 Prostate, Breast, and Other Cancers and Tumors0.186 RAF

Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.

Medicare coverage

D03.9 is named in 21 Medicare coverage policies 21 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.

  • A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
  • A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
  • A52479Oral Anticancer Drugs - Policy Article
  • A52479Oral Anticancer Drugs - Policy Article

How D03.9 is indexed

Coders do not find codes by browsing the tabular list — they look them up in the alphabetic index, under the word the physician wrote. These are the index entries that lead here, so you can see which chart wordings map to D03.9.

  • Melanomain situ
  • Melanomain situnail

Related codes at this level

Codes that share D03. If D03.9 is not quite right, the correct code is usually one of these.

Questions about D03.9

Is D03.9 a billable ICD-10-CM code?
Yes. D03.9 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
Where does D03.9 sit in the tabular list?
Neoplasms (C00-D49), in the block In situ neoplasms (D00-D09).
ICD-10-CMFY2026-Apr· effective April 1, 2026

Loaded directly from the CMS/NCHS ICD-10-CM public-domain release — see data sources and our editorial policy. If this page disagrees with the CMS tabular list, this page is wrong. Reference information for professional coders; not medical or billing advice.